You are here

Articles

published: 10 June 2017

Natural Killer Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation

categories:

published: 13 May 2017

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy

categories:

published: 2 April 2017

Strategies for Stopping TKIs Growing Clearer

categories:

published: 8 January 2017

DESTINY: CML Patients With Stable Molecular Responses Safely Halved TKI Dose

categories:

published: 8 January 2017

Adding Pioglitazone Could Improve Molecular Response in CML Patients

categories:

published: 13 December 2016

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in CML

categories:

published: 8 December 2016

Outcomes of the EURO-SKI Trial and the British DESTINY Study Reported ASH Meeting in San Diego Show that Reducing or Stopping a TKI Can Be Safe and Beneficial for Some Patients with CML

categories:

published: 15 November 2016

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With CML

categories:

published: 17 September 2016

Closer to a Cure? Researchers at centres in the US and Scotland have discovered ways to target Leukaemic Stem Cells (LSCs).

categories:

published: 16 September 2016

Webcast link for the CML Patient Day 2016 - Saturday, 24th September

categories:

published: 10 September 2016

ABL001 for Treating CML: Timothy P. Hughes, MD

categories:

published: 7 September 2016

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

categories:

published: 2 September 2016

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

categories:

published: 4 August 2016

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in CML

categories:

published: 4 August 2016

The concept of treatment-free remission in CML

categories:

published: 18 July 2016

Dasatinib in imatinib resistant or intolerant chronic phase Chronic Myeloid Leukaemia patients: 7-year follow-up of study CA180-034

categories:

published: 21 May 2016

PegIFN Improves Responses to Dasatinib in Newly Diagnosed CML Patients

categories:

published: 5 May 2016

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

categories:

published: 15 April 2016

European LeukemiaNet Recommendations for the Management of CML

categories:

published: 6 April 2016

Mtss1 is a critical epigenetically regulated tumor suppressor in CML

categories: